leadf
logo-loader
viewSerco Group
(
LSE:SRP
)

Serco taps US private placement market

The company has raised £154mln through the issue of loan notes at a lower interest rate than its current loan notes, which are set to mature next year

Serco

Serco Group PLC (LON:SRP) has beefed up its balance sheet through the issue of US$200mln (£154mln) of US private placement loan notes.

The notes have maturities of 5, 7, 10 and 12 years, with a weighted average maturity of nearly eight years, the outsourcing outfit told investors.

The average interest rate on the new loan notes is fixed at 3.6%, which compares to a blended rate of 5.3% for the group’s existing loan notes, which are scheduled for repayment next year.

In a statement, Serco said: "A strong capital structure is essential in providing a base for the ongoing execution of our strategy.  We are therefore pleased to be able to secure long term debt at attractive interest rates. 

"This is the first time Serco has accessed the US Private Placement market in more than seven years and was possible due to our low financial leverage and resilient business model."

Quick facts: Serco Group

Follow
LSE:SRP

Price: 137.1 GBX

Market Cap: £1.67 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

1 day, 11 hours ago

2 min read